ReviewJournal of translational medicine2026
Insights into programmed cell death from multiple imaging modalities.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death (PCD) is a fundamental, genetically regulated process crucial for development and homeostasis in multicellular organisms. Despite its importance, studying PCD presents significant challenges. Traditional methods relying on static, fixed samples cannot capture the dynamic progression of PCD and rarely reproduce the complex in vivo microenvironment. This review provides a systematic comparison of molecular probes and imaging modalities for detecting and differentiating major PCD subtypes, including apoptosis, necroptosis, and pyroptosis. We systematically summarize recent advances, emphasizing their utility for imaging‑based identification of distinct cell death forms rather than solely focusing on dynamic visualization. Practical guidance is offered for selecting appropriate probes and imaging platforms according to specific biological questions. By enabling real-time monitoring of hallmark markers and deep-tissue dynamics in living organisms, in vivo imaging provides novel insights and advanced technical support for elucidating the biological roles and functional significance of PCD. Nevertheless, this review highlights that the current strength of these technologies lies primarily in their ability to detect and differentiate PCD subtypes, with real‑time monitoring of full spatiotemporal dynamics remaining an ongoing challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.